PATENT CLAIM ANALYSIS

Application Number: 15986013
Application Type: Utility
Filing Date: 2018-05
Publication Date: 2018-11
Patent Classification: ["514", "027000"]

Abstract:
Compositions comprising LSF compositions and treatment regiments comprising administration of LSF containing compositions are disclosed. Compositions and/or regiments may optionally include the administration of vitamins, minerals, and anti-oxidants. Methods for using these compositions and treatment regimens for treating subjects for diseases, including diseases associated with inflammation and/or oxidative stress, are provided. Various methods for use of the LSF compositions for inhibition of histone deacetylases (HDACs) in various cells, tissues, and/or conditions are also provided.

Claim (Index 21):
A method for protecting cardiac myocytes in a cell, tissue or animal, comprising selecting a cell, tissue or animal comprising cardiac myocytes that has been contacted with doxorubicin and contacting said cell, tissue or animal with a composition comprising L-sulforaphane (LSF), an LSF derived and/or substituted compound, and/or an LSF analogue, wherein the LSF, LSF derived and/or substituted compound, and/or an LSF analogue has the following formula: wherein R is selected from the group consisting of hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted aryl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted acyl, ORa, SRa, SORa, SO2Ra, OSO2Ra, OSO3Ra, NO2, NHRa, N(Ra)2, \u2550N\u2014Ra, N(Ra)CORa, N(CORa)2, N(Ra)SO2R\u2032, N(Ra)C(\u2550NRa)N(Ra)Ra, CN, halogen, CORa, COORa, OCORa, OCOORa, OCONHRa, OCON(Ra)2, CONHRa, CON(Ra)2, CON(Ra)ORa, CON(Ra)SO2Ra, PO(ORa)2, PO(ORa)Ra, PO(ORa)(N(Ra)Ra) and amino acid ester having inhibitory efficacy against the LSD1 protein; and further wherein each of the Ra groups is independently selected from the group consisting of hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted aryl, and substituted or unsubstituted heterocyclyl, substituted or unsubstituted acyl; and further wherein each of the substituted or unsubstituted alkyl, alkenyl, alkynyl, aryl, heterocyclyl, and/or acyl groups are C1-28 (including all ranges therein), and protecting said cardiac myocytes in said cell, tissue or animal by reducing doxorubicin-induced DNA damage compared to a cell, tissue or animal contacted with doxorubicin and not contacted with said composition.

Metadata:
- Claim Count in Document: 41.0
- Percentile: 93.0
- Lexical Diversity: 1.65385
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['14793839', '14091742', '14823028', '15496866', '13485100']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7423791863763656
- 35 USC 102 Novelty (BERT): 0.6503749868317495
- Combined Prediction Score: 0.733178766421904
- Mean Citation Score: 338.89512
- Max Citation Score: 744.08704
- Similarity Product: 556.7355470077515

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test